HIV has been linked to an increase in severity of symptoms of PASC.

277 patients who had an outpatient follow-up or were readmitted to the hospital were reviewed. 27 patients had HIV and 22 followed up. There was no significant difference in age between HIV and non-HIV groups (55.3±11.3 vs 52.5±18.5 p>0.05) For HIV vs non-HIV patients with a history of COVID-19, numbness (18.2% vs 10.5%) paresthesias (9.1% vs 7.5%), brain fog or cognitive impairment (9.1% vs 6.7%), weakness (18.1% vs 27.1%), fatigue (31.2% vs 30.6%), headaches (18.1% vs 16.9%), changes in smell of taste (18.1% or 11.7), sleep issues or insomnia (13.6% vs 9.4%) and anxiety or depression (27.7% vs 18.0%) were reported between 4 weeks and 1 year after admission. Although there is an increased incidence of most neurological PASC symptoms in HIV compared to non-HIV, the difference did not reach significance.

This preliminary analysis of COVID-19 patients with 1 year follow-up demonstrates that the incidence of neurological symptoms of PASC in HIV patients vs non-HIV patients did not significantly differ. The incidence reported in this study agrees with prior literature on the incidence of neurological PASC. Work is in progress expand the study size and control for concomitant neurological conditions.